Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study.
Fiche publication
Date publication
septembre 2022
Journal
European journal of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Paupard T, Gonzalez F, Caron B, Siproudhis L, Peyrin-Biroulet L
Lien Pubmed
Résumé
Distal ulcerative colitis (UC) is responsible for distressing symptoms and reduces quality of life (QoL). Oral and topical formulations of 5-amino-salicylic acid are the first line therapy for mild to moderate distal UC.
Référence
Eur J Gastroenterol Hepatol. 2022 09 12;: